STEEP1: A Protein Targeted for Drug Treatment and Biomarker for Disease

Target Name: STEEP1

NCBI ID: G63932

STEEP1

STEEP1: A Protein Targeted for Drug Treatment and Biomarker for Disease

STEEP1 (also known as XLID107) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the STAR (S budget transduction RNA binding protein) family, which is known for its role in regulating gene expression and cell signaling.

Recent studies have identified STEEP1 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because STEEP1 has been shown to play a role in the regulation of cellular processes that are often disrupted in these conditions, such as inflammation, fibrosis, and cellular signaling abnormalities.

One of the key mechanisms by which STEEP1 is involved in these processes is its role in the regulation of NF-kappa-B signaling. NF-kappa-B is a protein that plays a role in the important transduction cascade that transduces cell signaling, and is involved in a wide range of cellular processes, including inflammation, stress response, and cell survival. STEEP1 has been shown to physically interact with NF-kappa-B and regulate its activity, which suggests that it may be a useful target for drugs that are designed to inhibit NF-kappa-B signaling.

In addition to its role in NF-kappa-B signaling, STEEP1 has also been shown to be involved in the regulation of other cellular processes that are often disrupted in diseases. For example, STEEP1 has been shown to play a role in the regulation of T cell receptor (TCR) signaling, which is important for the development and maintenance of the immune system. Similarly, STEEP1 has also been shown to be involved in the regulation of angiogenesis, which is the process by which new blood vessels are formed in the body.

These findings suggest that STEEP1 is a promising target for drugs that are designed to treat a wide range of diseases. For example, STEEP1 has been shown to be involved in the regulation of NF-kappa-B signaling, which is a key factor in the development of many diseases, including cancer and neurodegenerative disorders. Therefore, inhibitors of STEEP1 may be a useful treatment for these conditions.

In addition to its potential as a drug target, STEEP1 has also been shown to be a potential biomarker for a variety of diseases. For example, STEEP1 has been shown to be expressed in a variety of tissues and cells, including cancer cells, which suggests that it may be a useful biomarker for cancer. Additionally, STEEP1 has been shown to be involved in the regulation of cellular processes that are often disrupted in many diseases, such as T cell receptor signaling, which suggests that it may be a useful biomarker for autoimmune disorders.

Overall, STEEP1 is a protein that is involved in a wide range of cellular processes that are important for the development and maintenance of the body. Its role in the regulation of NF-kappa-B signaling and other processes suggests that it may be a useful target for drugs that are designed to treat a variety of diseases. Additionally, its potential as a biomarker for a wide range of conditions makes it an attractive target for researchers who are looking for new ways to diagnose and treat disease.

Protein Name: STING1 ER Exit Protein 1

Functions: Stimulates membrane curvature formation and subsequent endoplasmic reticulum exit site (ERES) establishment by recruiting PI3K complex I, leading to COPII vesicle-mediated transport (PubMed:32690950). Promotes endoplasmic reticulum (ER) exit of cGAMP-activated STING1 oligomers (PubMed:32690950)

The "STEEP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STEEP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets